Zentalis Pharmaceuticals Inc

NASDAQ:ZNTL  
50.91
-0.36 (-0.70%)
Earnings Announcements

Zentalis Pharmaceuticals Reports Third Quarter 2020 Financial Results And Operational Update

Published: 11/09/2020 12:17 GMT
(ZNTL) - Zentalis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Update.
Zentalis Pharmaceuticals Inc Qtrly Loss per Share $0.91.
Zentalis Pharmaceuticals Inc - Preparing to Initiate Phase 2 Trial of Zn-c5 in Patients With Advanced Breast Cancer in First Half of 2021.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.99

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.03

More details on our Analysts Page.